Chemical Compound
Bortezomib-pinanediol
CAS Registry Number
205393-22-2
Primary Record
Bortezomib-pinanediol
- In stock
- 7,752 g
- Purity
- 98.3 %
- CAS
- 205393-22-2
Compound Identifiers & Properties
- CAS
- 205393-22-2
- PubChem CID
- 16221476
- SMILES
- B1(O[C@@H]2C[C@@H]3C[C@H]([C@@]2(O1)C)C3(C)C)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)C5=NC=CN=C5
- Canonical SMILES
- CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B1O[C@@H]2C[C@@H]3C[C@@H](C3(C)C)[C@]2(C)O1
Names & Synonyms
- Bortezomib-pinanediol
- Bortezomib pinanediol
- 205393-22-2
- Bortezomib Pinanediol Ester
- Bortezomib Impurity 28
- Bortezomib Impurity 60
- BORTEZOMIBPINANEDIOLESTER
- MFCD11973734
- C29H39BN4O4
- Bortezomib Pinanediol Impurity
- HZCSTPSWJFWZHP-GQABWHEGSA-N
- CHEMBL501663
- orb1299444
- SCHEMBL8098845
- GLXC-20102
- AKOS015841786
- AKOS015950824
- ZINC169952278
- ACN-044348
- DS-4785
- FP27051
- AC-22608
- N-((S)-1-(((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide
- SC-22247
- SY490938
- HY-125939
- CS-0103201
- ST24046242
- Y0262
- J2.762.978D
- C73890
- 393B222
- A913145
- (1R)-(1S,2S,3R,5S)-Pinanediol-N-(N-pyrazinylphenylalaninoyl)-1-amino-3-methyl-butane-1-boronate
- N-[(2S)-1-[[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]amino]-1-oxo-3-phenylpropan-2-yl]pyrazine-2-carboxamide
- (1R)-(1S,2S,3R,5S)-Pinanediol-N-(N-pyrazinylphenylalaninoyl)-1-amino-3-methyl-butane-1-boronate (>90%)
- (1alpha,5alpha)-2,6,6-Trimethyl-2alpha,3alpha-[[(R)-1-[N-(pyrazine-2-ylcarbonyl)-L-phenylalanylamino]-3-methylbutyl]boranediylbisoxy]bicyclo[3.1.1]heptane
- (1R)-(1S,2S,3R,5S)-Pinanediol-N-(N-pyrazinylphenylalaninoyl)-1-amino-3-methylbutane-1-boronate (AK Sci)
- (2S)-N-[(1R)-3-METHYL-1-[(1S,2S,6R,8S)-2,9,9-TRIMETHYL-3,5-DIOXA-4-BORATRICYCLO[6.1.1.0(2),?]DECAN-4-YL]BUTYL]-3-PHENYL-2-(PYRAZIN-2-YLFORMAMIDO)PROPANAMIDE
- (2S)-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]-3-phenyl-2-[(pyrazin-2-yl)formamido]propanamide
- N-[(1S)-1-[[[(1R)-1-[(3aS,4S,6S,7aR)-Hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborole-2-yl]-3-methylbutyl]amino]carbonyl]-2-phenylethyl]-2-pyrazinecarboxamide
- N-[(1S)-1-benzyl-2-[[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]amino]-2-oxo-ethyl]pyrazine-2-carboxamide
- N-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-Hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]-2-oxo-1- (phenylmethyl)ethyl]-2-pyrazinecarboxamide
- N-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-Hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-2-pyrazinecarboxamide
- N-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-Hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-2-pyrazinecarboxamide; Pyrazinecarboxamide, N-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]-2-oxo-1-(phenylmethyl)ethyl]- (9CI); Pyrazinecarboxamide, N-[2-[[1-(hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl)-3-methylbutyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, [3aS-[2[S*(R*)],3aa,4ss,6ss,7aa]]-
- N-[(S)-1-[[(R)-3-Methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl]butyl]amino]-1-oxo-3-phenylpropan-2-yl]pyrazine-2-carboxamide
- N-{(1R)-3-Methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide